About Us

Management Team

Management Team


Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genetically defined targets driving cancer growth. Though drug development can be risky and complicated, we work hard to navigate through these complexities for the benefit of patients.

  • Joshua H. Bilenker, M.D.
    Joshua H. Bilenker, M.D.
    Chief Executive Officer
  • Jacob S. Van Naarden
    Jacob S. Van Naarden
    Chief Business Officer
  • Jennifer Burstein, CPA
    Jennifer Burstein, CPA
    Vice President of Finance
  • Nisha Nanda, Ph.D.
    Nisha Nanda, Ph.D.
    Senior Vice President, Development Strategy
  • Sara Slifka
    Sara Slifka
    Vice President, Business Operations & Program Management

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Jacob S. Van Naarden serves as Chief Business Officer. In his previous roles, Mr. Van Naarden served in various biotechnology investing, operating, and advisory capacities.

Previously, Mr. Van Naarden served as a public equity biotechnology analyst at HealthCor Management, a multi-billion dollar healthcare-dedicated investment firm based in NYC. Prior to HealthCor, Mr. Van Naarden was an Associate at Aisling Capital, a multi-strategy healthcare investment firm based in NY. Mr. Van Naarden started his career in the Healthcare Group of the Investment Banking Division at Goldman Sachs.

Mr. Van Naarden received his A.B. degree in molecular biology from Princeton University, graduating magna cum laude and Phi Beta Kappa.

Jennifer Burstein serves as VP of Finance.

Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance.

Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting.

Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.

Dr. Nanda serves as Senior Vice President of Development Strategy. Dr. Nanda has had increasing roles of responsibility in both clinical and pre-clinical development. Most recently Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo).

Dr. Nanda’s career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and Cor.

Dr. Nanda has a BSc Hons in Biochemistry and Molecular Genetics from UNSW, Sydney, Australia and a PhD in Biochemistry and Molecular Genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.

Sara Slifka serves as Vice President of Business Operations and Program Management. Previously, Ms. Slifka was a Vice President in Equity Research at Morgan Stanley covering the biotech sector.

In her prior role, Ms. Slifka analyzed small and large cap biotechnology companies from a financial, clinical, regulatory and commercial perspective.

Ms. Slifka received her A.B. degree from Princeton University.